In Depth 4 Dec 2024 Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner. December 4, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 2 Dec 2024 The rise of cancer vaccines: A new era in immunotherapy Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors. December 2, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 27 Nov 2024 Charcot–Marie–Tooth disease: what’s going on in the clinical field? In this article, we take a look at the various treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease. November 27, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 22 Nov 2024 Can AlphaFold3’s open-source platform revolutionize the way we discover drugs? Find out how Google DeepMind’s AlphaFold3 platform could help scientists revolutionize the field of drug discovery. November 22, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 21 Nov 2024 Huntington’s disease: a therapeutic field on a bumpy ride For years, biotechs have been trying to develop medicines to cure the disease but much to no avail. Now, as clinical studies advance, there is hope. November 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 20 Nov 2024 Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024 The hypoparathyroidism treatment space has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials. November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 18 Nov 2024 What is Abcam’s founder, Jonathan Milner, up to? Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy. November 18, 2024 - 17 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 13 Nov 2024 Sleep apnea: biotechs snore points in the therapeutic space Therapeutic strides in biotech are proving to help address different stages of the sleep apnea. November 13, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 11 Nov 2024 Gene editing sector investment struggles: What’s driving the slowdown? Find out what is driving the slowdown in gene therapy investment, as the sector continues to struggle with widespread layoffs. November 11, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 Nov 2024 The biggest private biotech investments in October 2024 The companies Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics bagged the biggest private biotech investments in October 2024. November 7, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Nov 2024 Tuberculosis research: Are we finally close to developing a more effective treatment option? Learn more about the positive advancements that have been made in tuberculosis research in an attempt to find new treatment options. November 6, 2024 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2024 From consumer health to pure biopharma: Inside Sanofi’s strategic shift Delve into Sanofi’s “play to win” strategy as investments are ramping up after their consumer health division’s divestment. November 5, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email